biostudies-literatureUnknown11(45)Amaar YG<h4>Introduction</h4>Recently we have identified a novel RASSF1C-PIWIL1-piRNA pathway that promotes lung cancer cell progression and migration. PIWI-like proteins interact with piRNAs to form complexes that regulate gene expression at the transcriptional and translational levels. We have illustrated in previous work that RASSF1C modulates the expression of the PIWIL1-piRNA gene axis, suggesting the hypothesis that the RASSF1C-PIWI-piRNA pathway could potentially contribute to lung cancer stem cell development and progression, in part, through modulation of gene methylation of both oncogenic and tumor suppressor genes. Therefore, we tested this hypothesis using a non-small cell lung cancer (NSCLC) cell model to identify Candidate Differentially Methylated Regions (DMRs) modulated by the RASOncotarget4082-4092https://www.ebi.ac.uk/biostudies/studies/S-EPMC7665232biostudies-literatureThe impact of the RASSF1C and PIWIL1 on DNA methylation: the identification of GMIP as a tumor suppressor.PMC7665232Reeves MEAmaar YGfalseThe impact of the RASSF1C and PIWIL1 on DNA methylation: the identification of GMIP as a tumor suppressor.<h4>Introduction</h4>Recently we have identified a novel RASSF1C-PIWIL1-piRNA pathway that promotes lung cancer cell progression and migration. PIWI-like proteins interact with piRNAs to form complexes that regulate gene expression at the transcriptional and translational levels. We have illustrated in previous work that RASSF1C modulates the expression of the PIWIL1-piRNA gene axis, suggesting the hypothesis that the RASSF1C-PIWI-piRNA pathway could potentially contribute to lung cancer stem cell development and progression, in part, through modulation of gene methylation of both oncogenic and tumor suppressor genes. Therefore, we tested this hypothesis using a non-small cell lung cancer (NSCLC) cell model to identify Candidate Differentially Methylated Regions (DMRs) modulated by the RAS2020-01-01T00:00:00Z2020 Nov2026-04-30T05:24:39.279Z2021-02-20T00:57:18ZS-EPMC76652323322708810.18632/oncotarget.27795